What are you looking for?

Dr. Lazar is Co-Founder and Chief Scientific Officer at Dualitas Therapeutics. Prior to Dualitas he led research groups at Genentech, Eli Lilly, and Xencor. Together with colleagues, Dr. Lazar has developed multiple technologies for optimizing antibodies and therapeutic proteins, and contributed to numerous clinical stage molecules including several approved drugs. He is an inventor of over 30 patents and has authored over 40 scientific publications in the fields of protein design, biotherapeutic engineering, and drug discovery. Dr. Lazar holds a BS in Molecular & Cell Biology with Chemistry Honors from Penn State and a PhD in Molecular & Cell Biology from UC Berkeley, and was a Jane Coffin Childs Fellow at the University of Cambridge.

While there has been substantial innovation in bispecific engineering, approaches to bispecific discovery have thus far been narrowly focused on pre-determined target pairs of known biology to often realize incremental gains. Dualitas has built a bispecific discovery engine that operates at combinatorial scale, enabling functional screening of cell surfaceomes at vast target and epitope space. Large unbiased screens have illuminated novel co-target biology and yielded an emerging bispecific pipeline of I&I programs with differentiated activities unachievable by conventional inhibitors. Moreover, observations of repeatable activities are elucidating a novel collection of immune engagers, plug-and-playable mechanisms and antibody arms that can bring superior pharmacology to established therapeutic pathways.